Actavis plc, of Dublin, said it plans to acquire Forest Laboratories Inc., of New York, for a combination of cash and equity valued at approximately $25 billion or $89.48 per Forest share ($26.04 in cash and 0.3306 Actavis shares for each share of Forest common stock).